Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06565195 | A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease | PHASE1 | RECRUITING | 124 | — | — | Aug 27, 2024 | May 5, 2029 | May 18, 2026 | 4 | United States, Japan |
| Arm | Type | Description |
|---|---|---|
| LY3962681 (SAD) | EXPERIMENTAL | Single ascending dose of LY3962681 or placebo (aCSF) administered intrathecally (IT) to healthy volunteers. |
| LY3962681 (MAD) | EXPERIMENTAL | Multiple ascending doses of LY3962681 or placebo (aCSF) administered IT to participants with Parkinson's disease. |
| Name | Type | Description |
|---|---|---|
| LY3962681 | DRUG | IT injection |
| Placebo (aCSF) | OTHER | IT injection |
Inclusion Criteria: * Participant is overtly healthy as determined by medical evaluation. Rescreening is allowed in this study. * A Montreal Cognitive Assessment score greater than or equal to 24. * Stable use of background medications at least 8 weeks prior to IP administration, including but not ...